Dr. Sartor on Distinguishing Between Symptomatic and Asymptomatic Patients

Oliver Sartor, MD
Published: Wednesday, Apr 16, 2014

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the distinction between symptomatic and asymptomatic patients with bone metastases from prostate cancer.

The FDA indication for radium-223 states that patients should have symptomatic disease, though Sartor says he is unsure of the true importance of this. As pain tolerance varies, Sartor says, he does not factor it into his decision — he is more likely to consider the burden of bony disease.

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the distinction between symptomatic and asymptomatic patients with bone metastases from prostate cancer.

The FDA indication for radium-223 states that patients should have symptomatic disease, though Sartor says he is unsure of the true importance of this. As pain tolerance varies, Sartor says, he does not factor it into his decision — he is more likely to consider the burden of bony disease.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x